Tag Archives: Could

AbbVie pegs growth to booming Skyrizi, Rinvoq in post-merger future. But neurology could be a ‘sleeper’

With its $ 63 billion merger with Allergan in the rearview, the new AbbVie is facing a major challenge as U.S. biosimilars for Humira cast a pall over the near-term future. But AbbVie figures its homegrown prospects will keep driving growth—and a couple of surprises from Allergan could make the forecast even rosier.  After six… Read More »

Brain ‘signature’ could help to diagnose schizophrenia

People with schizophrenia and their healthy siblings share patterns of brain activity that are different from those seen in individuals with no family history of the disorder, scientists from EPFL have found. Because the siblings do not show schizophrenia symptoms, this brain ‘signature’ could serve as a marker for the early diagnosis of the disorder.… Read More »

Online GPs could save employers £1.5 billion in lost working time, according to report

Employee travel to GP appointments cost UK businesses an estimated £1.5 billion in lost working time last year, says a report published by the health insurance firm AXA PPP Healthcare today. The report, Digital health: the changing landscape of how we access GP services, produced by the Centre for Economics and Business Research (CEBR), highlights… Read More »